Investigating how reactive oxygen species affect heart cell development and injury response in newborns
The role of neonatal ROS in cardiomyocyte maturation and injury response
This study is looking at how certain molecules called reactive oxygen species (ROS) affect the growth and healing of heart cells in baby mice, with the hope that understanding this could lead to new ways to help hearts recover from injuries and improve their overall health.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-11031321 on NIH RePORTER |
What this research studies
This research explores the role of reactive oxygen species (ROS) in the maturation of heart cells (cardiomyocytes) and their response to injury in neonatal mice. By using a specific viral vector (AAV9) to manipulate ROS levels, the study aims to understand how these molecules influence the transition from regenerative to non-regenerative heart tissue. The research will assess whether controlling ROS can enhance the heart's ability to tolerate ischemic injury and promote metabolic changes essential for heart cell maturation. This work could provide insights into potential therapeutic strategies for heart disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with ischemic heart disease or those at risk of heart injury, particularly in the context of neonatal care.
Not a fit: Patients with non-ischemic heart conditions or those who are not neonates may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance heart regeneration and improve outcomes for patients with ischemic heart disease.
How similar studies have performed: While the role of ROS in heart development is a well-studied area, the specific approach using AAV9 to manipulate ROS levels in neonatal cardiomyocytes is relatively novel and has not been extensively tested.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Walker, Allison Trouten — Medical University of South Carolina
- Study coordinator: Walker, Allison Trouten
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.